

Groupe d'experts Unicancer	Etudes	Type de présentation	Titre	Auteurs	Affiliations	# Abstract et lien	Session / Date / Intervenants
GETUG	GETUG21-PEACE1	Poster	<i>Effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features in the PEACE-1 trial</i>	Alice Bernard-Tessier ¹ , Mathilde Cancel ² , Bertrand Tombal ³ , Guilhem Roubaud ⁴ , Joan Carles ⁵ , Aude Fléchon ⁶ , Ray McDermott ⁷ , Stéphane Supiot ⁸ , Dominik Berthold ⁹ , Philippe Ronchin ¹⁰ , Gabriel Kacso ¹¹ , Gwenaëlle Gravis ¹² , Fabio Calabro ¹³ , Jean-François Berdah ¹⁴ , Ali Hasbini ¹⁵ , Francesco Ricci ¹⁶ , Christophe Hennequin ¹⁷ , Hélène Ribault ¹⁸ , Stéphanie Foulon ¹ , Prof Karim Fizazi ¹	1 Institut Gustave Roussy, Villejuif, France2 Medical Oncology, Centre Hospitalo-Universitaire Bretonneau, Tours, France3 Urology, Cliniques Universitaires St. Luc - Université Catholique de Louvain, 1200 - Brussels/BE4 Medical Oncology, Institute Bergonié, 33000 - Bordeaux/FR5 Servicio de Oncología, Instituto de Oncología de la Vall d'Hebron, Barcelona, Spain6 Department Of Medical Oncology, Centre Léon Bérard, 69373 - Rhones-Alpes/FR7 Oncology (medical Oncology), St Vincent's University Hospital and Cancer Trials Ireland, Dublin/IE8 Radiotherapy, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR9 Medical Oncology Department, CHUV - Centre Hospitalier Universitaire Vaudois, 1011 - Lausanne/CH10 Radiotherapy, Centre Azuréen de cancérologie, Mougins/FR11 Radiotherapy, Centre Azuréen de cancérologie, Mougins/FR12 Medical Oncology Dept., IPC - Institut Paoli-Calmettes, 13273 - Marseille, Cedex/FR13 Medical Oncology, Azienda Ospedaliera S. Camillo Forlanini, 00152 - Rome/IT14 Medical Oncology, Clinique Sainte-Marguerite, 83400 - Hyères/FR15 Medical Oncology, Clinique Pasteur Lanroze, 29200 - Brest/FR16 Oncology, Institut Curie, Paris, France17 Radiotherapy, Centre Hospitalo-Universitaire Saint-Louis, Besançon/FR18 Unicancer, Paris, France	1421P	Session : Prostate cancer Speakers : Alice Bernard-Tessier (Villejuif, Cedex, France) Date : Sun, 11.09.2022
GETUG	GETUG21-PEACE1	Mini oral presentation	<i>8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase 3 trial</i>	G. Gravis Mescam ¹ , X. Maldonado ² , G. Roubaud ³ , R.S. McDermott ⁴ , A. Flechon ⁵ , B. Tombal ⁶ , S. Supiot ⁷ , D. Berthold ⁸ , R. Philippe ⁹ , G. Kacso ¹⁰ , F. Calabro ¹¹ , J.F. Berdah ¹² , A. Hasbini ¹³ , M. Silva ¹⁴ , A. Thiery-Vuillemin ¹⁵ , A. Rodriguez-Vida ¹⁶ , J. McCaffrey ¹⁷ , H. Ribault ¹⁸ , S. Foulon ¹⁹ , K. Fizazi ²⁰	1Institut Paoli-Calmettes, Aix-Marseille Université, CRCM, Marseille, Cedex, FR, 2Vall d'Hebron Institute of Oncology, Barcelona, ES, 3Institute Bergonié, Bordeaux, FR, 4St Vincent's University Hospital and Cancer Trials Ireland, Dublin, IE, 5Centre Léon Bérard, Lyon, FR, 6Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE, 7ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, 8CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, 9Centre Azureen Cancerologie, Mougins, FR, 10Amethyst Radiotherapy Center, Iuliu Hatienagu of Medicine and Pharmacy, Cluj-Napoca, RO, 11Azienda Ospedaliera San Camillo Forlanini, Rome, IT, 12Clinique Sainte-Marguerite, Hyères, FR, 13Clinique Pasteur Lanroze, Brest, FR, 14Centre François Baclesse, Caen, FR, 15CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, 16Hospital del Mar-IMIM Research Institute, Barcelona, ES, 17The Mater Misericordiae University Hospital, Dublin, IE, 18Unicancer, Paris, Cedex, FR, 19Gustave Roussy - University of Paris-SaclayOncostat U1018, Villej	1361MO	Mini Oral session : GU tumours, prostate Date : Sun, 11.09.2022 Speakers : Gwenaëlle Gravis Mescam (Marseille, Cedex 09, France) Lecture Time : 10:45 - 10:50
GETUG	GETUG-AFU 16 (Projet PROSPERO ou DADSPORT)	Mini oral presentation	<i>Duration of Androgen Suppression with post-operative radiotherapy (DADSPORT): An aggregate data meta-analysis</i>	S. Burdett ¹ , D. Fisher ¹ , C. Parker ² , M. Sydes ¹ , P. Pommier ³ , P. Sargos ⁴ , D. Spratt ⁵ , A. Kishan ⁶ , M. Brihoum ⁷ , C. Catton ⁸ , S. Chabaud ⁹ , N. Clarke ¹⁰ , A. Cook ¹ , I. Latorzeff ¹¹ , J. Tierney ¹ , C. Vale ¹	1Institute of Clinical Trials and Methodology, London, GB, 2The Royal Marsden Hospital (Sutton) - NHS Foundation Trust, Sutton, GB, 3CRCL - Centre de recherche en cancerologie de Lyon, Lyon, Cedex, FR, 4Institute Bergonié, Bordeaux, FR, 5Case Western Reserve University / University Hospitals, Cleveland, US, 6Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, 7Unicancer, Paris, Cedex, FR, 8Princess Margaret Cancer Center, Toronto, CA, 9Centre de recherche en cancerologie de Lyon (CRCL), Lyon, FR, 10The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB, 11Clinique Pasteur, Toulouse, FR	LBA64	Mini Oral session : GU tumours, prostate Date : Sun, 11.09.2022 Speakers : Sarah Burdett (London, United Kingdom) Lecture Time : 10:20 - 10:25

Groupe d'experts Unicancer	Etudes	Type de présentation	Titre	Auteurs	Affiliations	# Abstract et lien	Session / Date / Intervenants
UCGI	PRODIGE 63 – UCGI 36 – GEMPAX	Oral	<i>Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in Metastatic Pancreatic Ductal Adenocarcinoma: Results of the randomized phase III PRODIGE 63 – UCGI 36 – GEMPAX UNICANCER study</i>	C. De La Fouchardiere 1, D. Malka 2, S. Chabaud 3, J. Raimbourg 4, D. Botsen 5, S. Launay 6, L. Evesque 7, A. Vienot 8, H. Perrier 9, M. Jary 10, Y. Rinaldi 11, C. Coutzac Bergouignan 1, J.-B. Bachet 12, C. Neuzillet 13, N. Williet 14, R. Desgrrippes 15, G. Brard 16, N. Lachaux 16, O. Bouche 17, F. Ghiringhelli 18	1Centre Léon Bérard, Lyon, FR, 2Institut Gustave Roussy, Villejuif, Cedex, FR, 3Centre de recherche en cancerologie de Lyon (CRCL), Lyon, FR, 4ICO Institut de Cancerologie de l'Ouestren Gauducheau, Saint-Herblain, FR, 5Institut Jean Godinot, Reims, FR, 6IPC - Institut Paoli-Calmettes, Marseille, FR, 7Centre Anticancer Antoine Lacassagne, Nice, FR, 8CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, 9Fondation Hôpital Saint Joseph, Marseille, FR, 10CHU de ClermontFerrand - Site Estaing, Clermont-Ferrand, Cedex, FR, 11Hopital Européen Marseille, Marseille, FR, 12Groupe Hospitalier Pitié Salpetriere, Paris, FR, 13Institut Curie, Paris, FR, 14Hopital Nord, St Priest En Jarez, FR, 15C.H. Broussais, Saint-Malo, FR, 16UNICANCER, Paris, FR, 17CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR, 18University of Burgundy, Genetic and Immunotherapy Medical	LBA60	Proffered Paper session 2 : GI, upper digestive Date : Sun, 11.09.2022 Speakers : Christelle De la Fouchardiere (Lyon, France) Lecture Time : 15:15 - 15:25
UCBG	CANTO Life	Mini oral presentation	<i>Dissecting sexual health after breast cancer (BC) by longitudinal assessment of patient reported outcomes</i>	M.A. Franzoi 1, M. Aupomerol 2, J. Havas 1, H. Hang 1, A. Di Meglio 1, M. Lambertini 3, C. Massarotti 3, C. Coutant 4, O. Tredan 5, F. Joly Lobbedez 6, P. Cottu 7, D. Soldato 3, M.-A. Mouret 8, C. Tarpin 9, A. Arnaud 10, L. Fasse 2, S. Everhard 11, A.-L. Martin 14, B. Pistilli 1, M. Lambertini 15, I. Vaz Luis 1, A. Di Meglio 1	1Institut Gustave Roussy, Villejuif, Cedex, FR, 2Institut Gustave Roussy, Villejuif, FR, 3IRCCS Ospedale Policlinico San Martino, Genova, IT, 4Centre Georges Francois Leclerc, Dijon, FR, 5Medical Oncology, Lyon, FR, 6Centre Francois Baclesse, Caen, Cedex, FR, 7Institut Curie, Paris, FR, 8Centre Jean PERRIN, Clermont-Ferrand, Cedex, FR, 9IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, 10Institut SainteCatherine, Avignon, FR, 11UNICANCER, Paris, FR	1558MO	Mini Oral session : Supportive and palliative care Date : Sat, 10.09.2022 Speakers : Maria Alice Franzoi (Villejuif, France) Lecture Time : 17:10 - 17:15
UCBG	CANTO Life	Oral	<i>Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): results from the prospective CANTO cohort study</i>	R. Kabirian 1, J. Havas 1, M.A. Franzoi 1, C. Coutant 2, O. Tredan 3, C. Levy 4, P. Cottu 5, A. Dhaini Merimeche 6, S. Guillermet 7, J.-M. Ferrero 8, S. Giacchetti 9, T. Petit 10, F. Dalenc 11, P. Rouanet 12, O. Querel 13, A.-L. Martin 14, B. Pistilli 1, M. Lambertini 15, I. Vaz Luis 1, A. Di Meglio 1	1Institut Gustave Roussy, Villejuif, Cedex, FR, 2Centre Georges Francois Leclerc, Dijon, FR, 3Centre Léon Bérard, Lyon, FR, 4Centre Francois Baclesse, Caen, FR, 5Institut Curie, Paris, FR, 6Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, 7Centre Eugene - Marquis, Rennes, FR, 8Centre Antoine Lacassagne, Nice, FR, 9Hopital Saint Louis - Groupe Hospitalier La Rochelle-Ré-Aunis, La Rochelle, FR, 10Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, 11Centre Claudius-Regaud, Toulouse, FR, 12CRLC Val d'Aurelle, Montpellier, FR, 13Unicancer, Paris, Cedex, FR, 14UNICANCER, Paris, FR, 15IRCCS Ospedale Policlinico San Martino, Genova, IT	1551O	Proffered Paper session : Supportive and palliative care Date : Sun, 11.09.2022 Speakers : Rayan Kabirian (Villejuif, Cedex, France) Lecture Time : 08:30 - 08:40
UCBG	CANTO (RACE AI)	Poster	<i>Blind validation of an AI-based tool for predicting distant relapse from breast cancer HES stained slides</i>	Ingrid J. Garberis		147P	Session : Breast cancer, early stage Speakers : Ingrid J. Garberis (Villejuif, France) Date : Sat, 10.09.2022
UCGI	PRODIGE 24- ACCORD 24	Poster	<i>Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): an ancillary study of the PRODIGE-24 clinical trial</i>	Remy Nicolle	APHP (Hopital Beaujon)	1297P	Session : Pancreatic cancer Speakers : Remy Nicolle (Paris, France) Date : Mon, 12.09.2022
UCGI	UCGI 27- PRODIGE28 - TIME	Poster	<i>Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: final results of the randomized phase 2 TIME-PRODIGE28 UNICANCER study</i>	Valerie Boige, Eric Francois, Hélène Blons, Meher BEN Abdelghani, Jean Marc Phelip, Valerie Le Brun-Ly, Laurent Mineur, Marie Pierre Galais, Anne-Laure Villing, Vincent Hautefeuille, Laurent Miglianico, Christelle De La Fouchardiere, Dominique Genet, Nadia Levasseur, Nicolas Lachaux, Sophie Gourgou, Florence Castan, Olivier Bouché	Gustave Roussy, Villejuif, France; Centre Antoine-Lacassagne, Nice, France; Hopital Européen Georges Pompidou, Paris, France; Centre Paul Strauss, Strasbourg, France; Saint Etienne University Hospital, Saint Priest En Jarez, France; CHU Limoges - Hôpital Dupuytren, Limoges, France; Institut Sainte-Catherine, Avignon, France; Centre François Baclesse, Caen, France; CH d'Auxerre, Auxerre, France; Amiens University Hospital, Amiens, France; Centre Hospitalier Privé Saint-Grégoire, Saint Gregoire, France; Centre Léon Bérard, Lyon, France; Clinique François Chénieux, Limoges, France; CH Jean Rougier, Cahors, France; Polyclinique Francheville, Unicancer – UCGI group, Paris, Biometrics Unit, CTD INCa, ICM-Montpellier Cancer Institute, Univ Montpellier, Montpellier, France; CHU Robert Debré, Reims, France	387P	Session : Colorectal cancer Speakers : Valerie Boige (Villejuif, Cedex, France) Date : Sun, 11.09.2022

Groupe d'experts Unicancer	Etudes	Type de présentation	Titre	Auteurs	Affiliations	# Abstract et lien	Session / Date / Intervenants
UCGI	ACCORD 26- PRODIGE 29- NEOPAN	Mini oral presentation	<i>PRODIGE 29-UCGI 26 (NEOPAN): A Phase III randomised trial comparing chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC).</i>	M. Ducreux 1, R. Desgrippes 2, Y. Rinaldi 3, F. Di Fiore 4, R. Guimbaud 5, P. Follana 6, J.-B. Bachet 7, P. Vanelslander 8, T. Lecomte 9, O. Capitain 10, A. Parzy 11, M. Bolliet 12, P.-L. Etienne 13, J. Forestier 14, F. El Hajbi 15, A.L. Bignon Bretagne 16, V. Ly Lebrun 17, N. De Sousa Carvalho 18, M. Texier 19, O. Bouche 20	1Gustave Roussy - Cancer Campus, Villejuif, FR, 2C.H. Broussais, Saint-Malo, FR, 3Hopital Européen Marseille, Marseille, FR, 4CHU de Rouen Normandie, Rouen, FR, 5Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, FR, 6Centre Anticancer Antoine Lacassagne, Nice, FR, 7Groupe Hospitalier Pitié Salpêtrière, Paris, FR, 8Hôpital Saint Claude, Saint-Quentin, FR, 9CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR, 10Centre Paul Papin, Angers, FR, 11Centre Francois Baclesse, Caen, FR, 12Hopitaux Civils de Colmar, Colmar, FR, 13Hôpital Privé des Côtes d'Armor, Plérin sur mer, FR, 14Hopital Edouard Herriot, Lyon, FR, 15Centre Oscar Lambret, Lille, FR, 16CHU de Caen - Hopital Cote de Nacre, Caen, FR, 17CHU Limoges - Hopital Dupuytren, Limoges, FR, 18Unicancer, Paris, Cedex, FR, 19Institut Gustave Roussy, Villejuif, FR, 20CHU de Reims - Hôpital Robert Debré,	1296MO	Mini Oral session : GI, upper digestive Date : Sat, 10.09.2022 Speakers : Michel P. Ducreux (Villejuif, France) Lecture Time : 14:50 - 14:55
H&N	ORL10- IMMUNEBOOST	Oral	<i>Neoadjuvant Nivolumab (N) before chemoradiation (CRT) in high-risk HPV driven Oropharynx Cancer (OPC): IMMUNEBOOST-HPV, a multicenter randomized phase 2 trial</i>	H. Mirghani 1, C. Even 2, A. Larive 3, H. Pere 4, J. Fayette 5, L. Geoffrois 6, F. Clatot 7, B. Calderon 8, Y. Tao 2, T.V.F. Nguyen 3, E. Fabiano 4, S. Kreps 4, D. Veyer 4, J. Puech 4, C. Badoual 1, F. Garic 9, A. Auperin 3, P. Blanchard 3	1European George Pompidou Hospital - APHP, Paris, FR, 2Institut Gustave Roussy, Villejuif, Cedex, FR, 3Gustave Roussy - Cancer Campus, Villejuif, FR, 4HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, 5Centre Léon Bérard, Lyon, FR, 6Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, 7Centre Henri Becquerel, Rouen, FR, 8Institut SainteCatherine, Avignon, FR, 9Unicancer, Paris, Cedex, FR	653O	Proffered Paper session : Head & neck cancer Date : Mon, 12.09.2022 Speakers : Haitham Mirghani (Paris, France) Lecture Time : 15:35 - 15:45
Med Perso	DAISY	Poster	<i>Antitumor activity of Trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial</i>	N. Epailard1, A. Lusque2, B. Pistilli1, F. André1,3, T. Bachelot4, JY Pierga5, A. Ducoulombier6, C. Jouannaud7, F. Viret8, L. Salabert9, A. Johnson10, E. Deluche11, X. Durando12, T. Petit13, T. Filleron2, C. Mahier14, V. Diéras15, F. Mosele3	1Department of Medical Oncology, Gustave Roussy, Villejuif, France; 2Department of Biostatistics, Institut Claudius Regaud, IUCT-O, Toulouse, France; 3INSERM U981, Gustave Roussy, Villejuif, France; 4Department of Medical Oncology, Centre Léon Bérard, Lyon, France; 5Department of Medical Oncology, Institut Curie, Paris, France; 6Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France; 7Department of Medical Oncology, Institut Jean Godinot, Reims, France; 8Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France; 9Department of Medical Oncology, Institut Bergonié, Bordeaux, France; 10Department of Medical Oncology, Centre François Baclesse, Caen, France; 11 Department of Medical Oncology, CHU Dupuytren, Limoges, France; 12Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France; 13Department of Medical Oncology, ICANS, Strasbourg, France; 14R&D Department, Unicancer, Paris, France; 15Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.	260P	Session : Breast cancer, metastatic Speakers : Nicolas Epailard (Paris, France) Date : Sat, 10.09.2022
Med Perso	DAISY	Mini oral presentation	<i>Unraveling the mechanism of action and resistance to Trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial</i>	M.F. Mosele 1, A. Lusque 2, V. Dieras 3, E. Deluche 4, A. Ducoulombier 5, B. Pistilli 6, T. Bachelot 7, F. Viret 8, C. Levy 9, Y. Pradat 1, D. Tran 10, N. Droin 6, M. Kobayashi 11, T. Kakewaga 11, M. Deloger 1, B. Job 6, M. Jimenez 12, M. Lacroix-Triki 13, F. André 1	1Gustave Roussy - Cancer Campus, Villejuif, FR, 2Institut Claudius Regaud IUCT-O, Toulouse, FR, 3Centre Eugene - Marquis, Rennes, FR, 4CHU Limoges - Hopital Dupuytren, Limoges, FR, 5Centre Anticancer Antoine Lacassagne, Nice, FR, 6Institut Gustave Roussy, Villejuif, Cedex, FR, 7Centre Léon Bérard, Lyon, FR, 8IPC - Institut Paoli-Calmettes, Marseille, FR, 9Centre Francois Baclesse, Caen, FR, 10Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR, 11Daiichi Sankyo Co., Ltd., Tokyo, JP, 12Unicancer, Paris, FR, 13Institut Gustave Roussy, Villejuif, FR	LBA72	Mini Oral session : Basic science & translational research Date : Sun, 11.09.2022 Speakers : Maria Fernanda Mosele (Villejuif, France) Lecture Time : 14:45 - 14:50
Med Perso	MOVIE	Poster	<i>Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): results of the tumor mutational burden-high (TMB-h) and/or microsatellite instability-high (MSI-h) cohort of the MOVIE study.</i>	A. Hervieu1, J. Guigay2, E. Borcoman3, P. Lavaud4, E. Coquan5, J.-S. Frenel6, T. De La Motte Rouge7, P. Augereau8, C. Cropet9, F. Legrand10, A. Goncalves11	1 Centre Georges-François Leclerc, Dijon, France; 2 Centre Anticancer Antoine Lacassagne, Nice, France; 3 Institut Curie, Paris, France; 4 Institut Gustave Roussy, Villejuif, France; 5 Centre Francois Baclesse, Caen, France; 6 ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, France; 7 Centre Eugene - Marquis, Rennes, France; 8 Centre Paul Papin, Angers, France; 9 Méthodologie, Centre Léon Bérard, Lyon, France; 10 UNICANCER R&D, Paris, France; 11 Institut Paoli Calmettes, Marseille, France	478P	Session : Developmental therapeutics Speakers : Alice Hervieu (Dijon, France) Date : Mon, 12.09.2022

Groupe d'experts Unicancer	Etudes	Type de présentation	Titre	Auteurs	Affiliations	# Abstract et lien	Session / Date / Intervenants
GETUG	GETUG AFU 26 - NIVOREN	Poster	<i>Impact of baseline levels of circulating cytokines according to BMI on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab within the GETUG-AFU 26 NIVOREN trial</i>	Emeline Colomba ¹ , Lucia Carril-Ajuria ¹ , Cécile Dalban ² , Lisa Derosa, Carolina Alves Da Costa, Elie Rassy ¹ , Sylvie Negrier ³ , Christine Chevreau ⁴ , Gwenaëlle Gravis ⁵ , Stéphane Oudard ⁶ , Brigitte Laguerre ⁷ , Delphine Borchiellini ⁸ , Philippe Barthelemy ⁹ , Marine Gross Goupil ¹⁰ , Lionel Geoffrois ¹¹ , Frederic Rolland ¹² , Antoine Thiery-Vuillemin ¹³ , Florence Joly ¹⁴ , Sylvain Ladoire ¹⁵ , Florence Tantot ² , Bernard Escudier ¹ , Nathalie Chaput, Laurence Albiges ¹		1480P	Session : Renal cancer Speakers : Emeline COLOMBA (Villejuif, Cedex, France) Date : Mon, 12.09.2022
H&N	TOPNIVO	Poster	<i>Patterns of radiological responses to anti-PD1 in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study</i>	Caroline Even; Alice Bernard-Tessier; Matthieu Texier; Oumaya Ben-Said; Mariana Iacob; Amaury Daste; Jérôme Fayette; Sylvie Zanetta; Gautier Lefebvre; Marie Vinches; Alison Johnson; Laurence Bozec; Esma Saada-Bouزيد; Isabelle Jallut; Florence Garic; Laure Monard; Jean Bourhis; Joël Guigay; Anne Auperin; Samy Ammari	IGR, Villejuif; IGR, Villejuif; IGR, Villejuif; IGR, Villejuif; IGR, Villejuif; CHU Bordeaux; CLB Lyon; CGFL, Dijon; COL Lille; ICM, Montpellier; Centre François Baclesse, Caen; Institut Curie, Paris; CAL, Nice; Unicancer; Unicancer; Unicancer; Lausanne University Hospital; CAL, Nice; IGR, Villejuif; IGR, Villejuif	675P	Session : Head and neck cancer, excluding thyroid Speakers : Caroline Even (Villejuif, Cedex, France) Date : Sun, 11.09.2022
UCBG	START	Mini oral presentation	<i>Primary endpoint analysis of a randomized phase 2 of darolutamide or capecitabine in patients with triple-negative androgen receptor positive advanced breast cancer (UCBG3-06 START trial)</i>	M. Arnedos 1, A. Goncalves 2, M. Pulido 3, F. Lerebours 4, O. Tredan 5, F. Dalenc 6, S. Guiu 7, D. Mollon Grange 8, L. Teixeira 9, C. Levy 10, B. Verret 11, H. Dawood 12, P. Augereau 13, L. Deiana 14, S. Ladoire 15, E. Carola 16, M.A. Mouret Reynier 17, C. Guyonneau 18, G. Macgrogan 19, H. Bonnefoi 19	1Institute Bergonié, Bordeaux, FR, 2Institute Paoli Calmettes, Marseille, FR, 3Institut Bergonie, BORDEAUX, FR, 4Hôpital René Huguenin - Institut Curie, St. Cloud, FR, 5Centre Léon Bérard, Lyon, FR, 6Centre Claudius-Regaud, Toulouse, FR, 7ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, 8Centre Hospitalier de Cornouaille - Site de Laennec, Quimper, Cedex, FR, 9Hopital Saint Louis AP-HP, Paris, FR, 10Centre Francois Baclesse, Caen, FR, 11Gustave Roussy, VILLEJUIF, FR, 12CHR Orléans, Orléans, FR, 13Centre Paul Papin, Angers, FR, 14CHRU Brest - Hopital Augustin Morvan, Brest, FR, 15Centre Georges-François Leclerc (Dijon), Dijon, FR, 16GHPSO, Creil, FR, 17Jean Perrin Center, Clermont-Ferrand, FR, 18Unicancer, Paris, FR, 19Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC),	213MO	Mini Oral session : Breast cancer, metastatic Date : Sat, 10.09.2022 Speakers : Monica Arnedos (Bordeaux, France) Lecture Time : 15:35 - 15:40
ESME	ESME CBP	Poster	<i>An adjusted comparison of amivantamab phase II data versus real-world clinical management in France of EGFR exon 20 insertion-mutated (ex20ins) advanced NSCLC patients</i>	Christos Chouaid		1122P	Session : NSCLC, metastatic Speakers : Christos Chouaid (Créteil, France) Date : Mon, 12.09.2022
ESME	ESME OVR	Poster	<i>CA125 longitudinal decline kinetic is complementary to BRCA testing in first-line high grade serous ovarian carcinoma (HGSOC) patients (pts)</i>	Ondine BECKER		596P	Session : Gynaecological cancers Speakers : Ondine BECKER (Paris, France) Date : Sun, 11.09.2022
ESME	ESME CSM	Poster	<i>Association between progression free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: Evidence from the ESME real-world database</i>	Coralie C. Courtinard		250P	Session : Breast cancer, metastatic Speakers : Coralie C. Courtinard (Bordeaux, Cedex, France) Date : Sat, 10.09.2022

Groupe d'experts Unicancer	Etudes	Type de présentation	Titre	Auteurs	Affiliations	# Abstract et lien	Session / Date / Intervenants
UCBG	Ribolaris (sponsor SOLTI)	Poster	<i>SOLTI-1911: Neoadjuvant and adjuvant ribociclib and endocrine therapy for clinically high-risk estrogen receptor-positive and HER2-negative breast cancer (RIBOLARIS)</i>	Paul Cottu ^{1,2} ; Aleix Prat ^{3,4,5,6} ; Tomas Pascual ^{3,4} ; Jérôme Lemonnier ⁷ ; Huilin Hu ⁸ ; Estelle Roux ⁹ ; Astrid Thuerigen ¹⁰ ; Roisin Connolly ¹¹ ; Cynthia X Ma ¹² ; Antonio Wolff ¹³ ; Thayane Crestani ¹⁴ ; Pablo Tolosa ^{2,15} ; Fernando Salvador ³ ; Thibault de La Motte Rouge ^{1,16} ; Joaquín Gaviá ^{3,17}	¹ UNICANCER; Paris, France; ² Institut Curie, Paris, France; ³ SOLTI Breast Cancer Research Group, Barcelona, Spain; ⁴ Hospital Clinic de Barcelona, Barcelona, Spain; ⁵ August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; ⁶ University of Barcelona, Barcelona, Spain; ⁷ UCBG UNICANCER, Paris, France; ⁸ Clinical development & Analytics, Novartis Pharmaceuticals Corp., East Hanover, United States of America; ⁹ Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States of America; ¹⁰ Oncology Medical Affairs, Novartis Pharma AG, Basel, Switzerland; ¹¹ Cancer Research, UCC - University College Cork, Cork, Ireland; ¹² Washington University School of Medicine in St. Louis, St. Louis, United States of America; ¹³ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; ¹⁴ Breast International Group (BIG) - AISBL, Brussels, Belgium; ¹⁵ Hospital Universitario 12 de Octubre, Madrid, Spain; ¹⁶ Centre Eugene - Marquis/GINECO, Rennes, France; ¹⁷ Fundación Instituto Valenciano de Oncología, Valencia, Spain.	203TiP	Session : Breast cancer, early stage Speakers : Paul H. Cottu (Paris, France) Date : Sat, 10.09.2022